Searched for: in-biosketch:yes
person:morgag04
Immunologic factors
Chapter by: Morgan, Gareth J; Linet, Martha S; Rabkin, Charles S
in: Cancer epidemiology and prevention by Schottenfeld, David; Fraumeni, Joseph F (Eds)
Oxford ; New York : Oxford University Press, 2006
pp. ?-?
ISBN: 9780195149616
CID: 3708752
The leukemias
Chapter by: Linet, Martha S; Devesa, Susan S; Morgan, Gareth J
in: Cancer epidemiology and prevention by Schottenfeld, David; Fraumeni, Joseph F (Eds)
Oxford ; New York : Oxford University Press, 2006
pp. ?-?
ISBN: 9780195149616
CID: 3708762
Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium
Rothman, Nathaniel; Skibola, Christine F; Wang, Sophia S; Morgan, Gareth; Lan, Qing; Smith, Martyn T; Spinelli, John J; Willett, Eleanor; De Sanjose, Silvia; Cocco, Pierluigi; Berndt, Sonja I; Brennan, Paul; Brooks-Wilson, Angela; Wacholder, Sholom; Becker, Nikolaus; Hartge, Patricia; Zheng, Tongzhang; Roman, Eve; Holly, Elizabeth A; Boffetta, Paolo; Armstrong, Bruce; Cozen, Wendy; Linet, Martha; Bosch, F Xavier; Ennas, Maria Grazia; Holford, Theodore R; Gallagher, Richard P; Rollinson, Sara; Bracci, Paige M; Cerhan, James R; Whitby, Denise; Moore, Patrick S; Leaderer, Brian; Lai, Agnes; Spink, Charlotte; Davis, Scott; Bosch, Ramon; Scarpa, Aldo; Zhang, Yawei; Severson, Richard K; Yeager, Meredith; Chanock, Stephen; Nieters, Alexandra
BACKGROUND:Common genetic variants in immune and inflammatory response genes can affect the risk of developing non-Hodgkin lymphoma. We aimed to test this hypothesis using previously unpublished data from eight European, Canadian, and US case-control studies of the International Lymphoma Epidemiology Consortium (InterLymph). METHODS:We selected 12 single-nucleotide polymorphisms for analysis, on the basis of previous functional or association data, in nine genes that have important roles in lymphoid development, Th1/Th2 balance, and proinflammatory or anti-inflammatory pathways (IL1A, IL1RN, IL1B, IL2, IL6, IL10, TNF, LTA, and CARD15). Genotype data for one or more single-nucleotide polymorphisms were available for 3586 cases of non-Hodgkin lymphoma and for 4018 controls, and were assessed in a pooled analysis by use of a random-effects logistic regression model. FINDINGS/RESULTS:The tumour necrosis factor (TNF) -308G-->A polymorphism was associated with increased risk of non-Hodgkin lymphoma (p for trend=0.005), particularly for diffuse large B-cell lymphoma, the main histological subtype (odds ratio 1.29 [95% CI 1.10-1.51] for GA and 1.65 [1.16-2.34] for AA, p for trend <0.0001), but not for follicular lymphoma. The interleukin 10 (IL10) -3575T-->A polymorphism was also associated with increased risk of non-Hodgkin lymphoma (p for trend=0.02), again particularly for diffuse large B-cell lymphoma (p for trend=0.006). For individuals homozygous for the TNF -308A allele and carrying at least one IL10 -3575A allele, risk of diffuse large B-cell lymphoma doubled (2.13 [1.37-3.32], p=0.00083). INTERPRETATION/CONCLUSIONS:Common polymorphisms in TNF and IL10, key cytokines for the inflammatory response and Th1/Th2 balance, could be susceptibility loci for non-Hodgkin lymphoma. Moreover, our results underscore the importance of consortia for investigating the genetic basis of chronic diseases like cancer.
PMID: 16389181
ISSN: 1470-2045
CID: 3706592
Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect
Dasgupta, R K; Rule, S; Johnson, P; Davies, J; Burnett, A; Poynton, C; Wilson, K; Smith, G M; Jackson, G; Richardson, C; Wareham, E; Stars, A C; Tollerfield, S M; Morgan, G J
Reduced intensity conditioning (RIC) for allogeneic stem cell transplantation allows stable donor cell engraftment with the maintenance of a graft versus malignancy effect. Many different regimens exist employing various combinations of chemotherapy, radiotherapy and T-cell depletion. We examined the role of non-T-cell depleted RIC regimens in 56 patients with haematological malignancies. Patients received fludarabine phosphate for 5 days (30 mg/m2 in 35 patients, 25 mg/m2 in 21 patients) and melphalan for 1 day (140 mg/m2 in 36 patients, 100 mg/m2 in 20 patients). Immunosuppression was with CyA alone in 33 patients and CyA/MTX in 23 patients. Twenty-four of the 26 patients with chimerism data showed >95% donor chimerism at 3 months post transplant. aGVHD occurred in 18% of patients receiving CyA/MTX compared to 53% of patients receiving CyA. The 100-day mortality rate was 0.16 (95%CI 0.08-0.28) and 1-year nonrelapse mortality was 0.24 (95%CI 0.13-0.38). Thirty-three patients remained alive and in CR at a median of 19 months post transplant (range 3-38 months). We have shown that patients transplanted with fludarabine phosphate, melphalan 100 mg/m2 and with CyA/MTX as post transplant immunosuppression can achieve good disease control with an acceptable level of toxicity. Further studies are required to confirm these findings.
PMID: 16435017
ISSN: 0268-3369
CID: 3706602
Parainfluenza type 3 infection post stem cell transplant: high prevalence but low mortality
Dignan, F; Alvares, C; Riley, U; Ethell, M; Cunningham, D; Treleaven, J; Ashley, S; Bendig, J; Morgan, G; Potter, M
Parainfluenza type 3 (PIV 3) is a well-recognized cause of respiratory illness after stem cell transplantation (SCT), with an estimated incidence of 2-7% and a high mortality rate associated with lower respiratory tract infection (LRTI). A 12-month retrospective study was undertaken in which 23 positive cases of PIV 3 occurred in SCT recipients. The frequency of infection was 36.1% in matched unrelated donor SCT recipients, 23.8% in sibling allogeneic SCT recipients and 2.3% in autologous transplant recipients. Seventeen cases were outpatient or community acquired despite standard infection control measures. Eleven patients only developed upper respiratory tract symptoms. LRTI symptoms developed in 12 patients, of whom eight had a new infiltrate on chest X-ray. Overall mortality at 30 days from PIV 3 diagnosis was 4% (one patient). Four patients died within 100 days of PIV 3 diagnosis, but PIV 3 was not believed to be the primary cause of death in any of these patients. Early ribavirin was used in eight patients and only one patient who received ribavirin died. These results suggest a higher prevalence of PIV 3 but a lower mortality than documented previously, particularly in allogeneic transplant recipients. The authors propose that the high prevalence reflects the unit's policy of active surveillance for respiratory viruses and the difficulty in preventing transmission of PIV 3, especially in the outpatient setting during an outbreak period. Ribavirin treatment may improve outcome in patients with LRTI but is not required in all patients with PIV 3.
PMID: 16772104
ISSN: 0195-6701
CID: 3706612
Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma
Chiecchio, L; Protheroe, R K M; Ibrahim, A H; Cheung, K L; Rudduck, C; Dagrada, G P; Cabanas, E D; Parker, T; Nightingale, M; Wechalekar, A; Orchard, K H; Harrison, C J; Cross, N C P; Morgan, G J; Ross, F M
In myeloma, the prognostic impact of different strategies used to detect chromosome 13 deletion (Delta13) remains controversial. To address this, we compared conventional cytogenetics and interphase fluorescence in situ hybridization (iFISH) in a large multicenter study (n=794). The ability to obtain abnormal metaphases was associated with a poor prognosis, which was worse if Delta13, p53 deletion or t(4;14) was present, but only Delta13 remained significant on multivariate analysis. Patients with Delta13, by either cytogenetics or iFISH, had a poor prognosis. However, when cases with Delta13 detectable by both cytogenetics and iFISH were separated from those detected by iFISH only, the poor prognosis of iFISH-detectable Delta13 disappeared; their outcome matched that of patients with no detectable Delta13 (P=0.115). Addition of ploidy status to iFISH-Delta13 did not affect the prognostic value of the test. Indeed both cytogenetics and iFISH Delta13 divided both hyperdiploidy and nonhyperdiploidy into two groups with similar prognoses, indicating that the poor prognosis of ploidy is entirely due to its association with Delta13. We conclude that Delta13 detected by metaphase analysis is a critical prognostic factor in myeloma. Absence of Delta13, even in those patients yielding only normal or no metaphases, is associated with a relatively good prognosis.
PMID: 16826223
ISSN: 0887-6924
CID: 3695782
International uniform response criteria for multiple myeloma
Durie, B G M; Harousseau, J-L; Miguel, J S; Bladé, J; Barlogie, B; Anderson, K; Gertz, M; Dimopoulos, M; Westin, J; Sonneveld, P; Ludwig, H; Gahrton, G; Beksac, M; Crowley, J; Belch, A; Boccadaro, M; Cavo, M; Turesson, I; Joshua, D; Vesole, D; Kyle, R; Alexanian, R; Tricot, G; Attal, M; Merlini, G; Powles, R; Richardson, P; Shimizu, K; Tosi, P; Morgan, G; Rajkumar, S V
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.
PMID: 16855634
ISSN: 0887-6924
CID: 3695792
Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma
Walker, Brian A; Leone, Paola E; Jenner, Matthew W; Li, Cheng; Gonzalez, David; Johnson, David C; Ross, Fiona M; Davies, Faith E; Morgan, Gareth J
Multiple myeloma is characterized by genomic alterations frequently involving gains and losses of chromosomes. Single nucleotide polymorphism (SNP)-based mapping arrays allow the identification of copy number changes at the sub-megabase level and the identification of loss of heterozygosity (LOH) due to monosomy and uniparental disomy (UPD). We have found that SNP-based mapping array data and fluorescence in situ hybridization (FISH) copy number data correlated well, making the technique robust as a tool to investigate myeloma genomics. The most frequently identified alterations are located at 1p, 1q, 6q, 8p, 13, and 16q. LOH is found in these large regions and also in smaller regions throughout the genome with a median size of 1 Mb. We have identified that UPD is prevalent in myeloma and occurs through a number of mechanisms including mitotic nondisjunction and mitotic recombination. For the first time in myeloma, integration of mapping and expression data has allowed us to reduce the complexity of standard gene expression data and identify candidate genes important in both the transition from normal to monoclonal gammopathy of unknown significance (MGUS) to myeloma and in different subgroups within myeloma. We have documented these genes, providing a focus for further studies to identify and characterize those that are key in the pathogenesis of myeloma.
PMID: 16705090
ISSN: 0006-4971
CID: 3647242
Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma
Walker, Brian A; Morgan, Gareth J
The genetics of multiple myeloma is a vastly studied field in which techniques such as classical cytogenetics, fluorescence in situ hybridization, and comparative genomic hybridization have been used. More recently, single nucleotide polymorphism (SNP)-based mapping arrays have become available that allow the identification of regions of gain or loss as small as 2.5 kb. In addition to the increased resolution of SNP-based arrays, the detection of loss of heterozygosity is also possible. This allows the identification of loss of heterozygosity regions that arise through monosomy and recombination, resulting in uniparental disomy, which cannot be detected by conventional genetic methods. In this review, we discuss the benefits of SNP-based arrays along with some of the drawbacks and how that data can be used in conjunction with expression data to identify genes with altered expression in regions of interest.
PMID: 17229333
ISSN: 1557-9190
CID: 3647312
New developments in the epidemiology of cancer prognosis: traditional and molecular predictors of treatment response and survival
Ambrosone, Christine B; Rebbeck, Timothy R; Morgan, Gareth J; Albain, Kathy S; Calle, Eugenia E; Evans, William E; Hayes, Daniel F; Kushi, Lawrence H; McLeod, Howard L; Rowland, Julia H; Ulrich, Cornelia M
PMID: 17119026
ISSN: 1055-9965
CID: 3647292